Notably, the most effective therapies for MS treatment target integrins [16], i.e., the ubiquitous transmembrane receptors that mediate cell-to-cell interaction [17], but the integrin engagement in astroglial direct interactions with CNS-IICs in MS has not been examined. This evidence concerns the gene NRP1 and myeloid sarcoma.